Is it Time to Buy 2012's Worst Biotechs?

The following video is part of our "Motley Fool Conversations" series, in which health-care editor/analyst David Williamson discusses topics across the investing world.

In this video, David takes a closer look at biotech's two worst stocks in 2012. Beaten down companies are often underperforming for a reason, but sometimes the negativity provides a nice entry point. Shares for both of these companies are off more than 50% after trial difficulties -- watch and discover which is a stay away and which may be a possible buy. 

Health-care investors are always looking for the next big breakthrough. Motley Fool co-founder David Gardner recently identified a small-cap health-care company that he believes is poised for monster returns. To uncover this top pick today, enjoy the special free report "Discover the Next Rule-Breaking Multibagger." Don't miss out on this limited-time offer and your opportunity to discover this game-changing company before the market does. Click here to access your report -- it's totally free.

At the time this article was published

Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story